NCT03662763View on ClinicalTrials.gov

Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity

PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

December 31, 2013

Conditions
Attention Deficit Disorder
Interventions
DRUG

Extended-release Guanfacine Hydrochloride (SPD503)

dosing in all subjects will initiate with 1mg/day, and may be increased by 1 mg increments after a minimum of 1 week on the current dose to the maximum doses based on age and weight.

DRUG

Placebo oral capsule

Trial Locations (1)

Unknown

Maastricht University Medical Centre, Maastricht

Sponsors

Collaborators (1)

Shire
All Listed Sponsors
collaborator

Shire

INDUSTRY

lead

Maastricht University Medical Center

OTHER